July 20, 2007
Boston Sci. reports falling stent sales
By Cory Hopkins
Domestic sales of Natick-based Boston Scientific's drug eluting coronary stent systems were down 41.96 percent in the second quarter of this year compared to the same time last year, the company said in its second-quarter earnings statement, released today.
Sales of the stent systems rang in at $249 million in the quarter ended June 30, 2007, compared to $429 million in 2006.
Worldwide, the company saw a 32.46 percent dip in drug eluting stent sales in the same period.
As a result, the company saw total net sales dip to $2.07 billion for the second quarter of 2007, down from $2.110 billion last year.
The company reported $115 million in net income for the second quarter, which translates to $.08 per share on 1.5 billion weighted shares outstanding.
Officials said the company estimates net sales for the third quarter between $2 billion and $2.1 billion, and earnings per share between $.03 and $.08.
Sales of the stent systems rang in at $249 million in the quarter ended June 30, 2007, compared to $429 million in 2006.
Worldwide, the company saw a 32.46 percent dip in drug eluting stent sales in the same period.
As a result, the company saw total net sales dip to $2.07 billion for the second quarter of 2007, down from $2.110 billion last year.
The company reported $115 million in net income for the second quarter, which translates to $.08 per share on 1.5 billion weighted shares outstanding.
Officials said the company estimates net sales for the third quarter between $2 billion and $2.1 billion, and earnings per share between $.03 and $.08.
WBJ Web Partners
Most Recent
Most Recent
0 Comments